西格玛-1受体加剧由阻塞性病引起的心脏功能障碍:性变异的作用
Francisco Javier Munguia-Galaviz1,2, Alejandra Guillermina Miranda-Diaz1, Yanet Karina Gutierrez-Mercado3
1Departamento de Fisiologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Biomedicines
|August 29, 2024
概括
西格玛-1受体 (Sigmar1) 恶化心综合征4型 (CRS4) 和心脏功能障碍,特别是在男性中. 西格玛1刺激会恶化损伤和心脏问题,突出显示CRS4发育的性别差异.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 西格玛-1受体 (Sigmar1) 是一种压力激活的伴侣,具有显著的治疗潜力.
- 4型心脏病综合征 (CRS4) 涉及损伤导致心脏功能障碍,但Sigmar1的作用尚不清楚.
- 了解Sigmar1在CRS4中的参与对于开发向治疗至关重要.
研究的目的:
- 调查Sigmar1及其连接体在CRS4由单边尿管阻塞 (UUO) 诱导的小鼠模型中的作用.
- 评估Sigmar1激动剂和对抗剂对和心脏功能障碍以及心脏重塑的影响.
- 探索Sigmar1对CRS4.4影响的潜在基于性别的差异.
主要方法:
- 在雄性和雌性C57BL/6小鼠中使用单边尿路阻塞 (UUO) 建立了一个CRS4模型.
- 小鼠接受了西格玛1激动剂 (PRE-084,SA4503) 或对抗剂 (haloperidol) 的治疗.
- 评估包括生物化学测定,RT-qPCR,组织学,免疫组织化学,ELISA,RNA-seq和21天内的生物信息学分析.
主要成果:
- 单边尿路阻塞 (UUO) 在脏和心脏中增加了Sigmar1的表达.
- 西格玛1激动剂 (PRE-084,SA4503) 在两性中加剧了心脏功能障碍和重塑.
- 这些加重效应在雄性小鼠中明显明显.
结论:
- 在CRS4期间,Sigmar1的表达在脏和心脏上升调节.
- 刺激Sigmar1恶化心脏功能障碍和CRS4的重塑,男性的影响更大.
- 在CRS4发育和Sigmar1作用的性别特异性差异需要考虑治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:31Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
01:26Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K
01:17Antihypertensive Drugs: Action of β1 Blockers
327
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
327